KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin (2016 - 2023)

Historic Gross Margin for TherapeuticsMD (TXMD) over the last 13 years, with Q4 2023 value amounting to 100.0%.

  • TherapeuticsMD's Gross Margin changed 0.0% to 100.0% in Q4 2023 from the same period last year, while for Dec 2023 it was 92.47%, marking a year-over-year decrease of 262200.0%. This contributed to the annual value of 100.0% for FY2023, which is 20000.0% up from last year.
  • According to the latest figures from Q4 2023, TherapeuticsMD's Gross Margin is 100.0%, which was down 0.0% from 100.0% recorded in Q3 2023.
  • In the past 5 years, TherapeuticsMD's Gross Margin registered a high of 2082.45% during Q1 2022, and its lowest value of 100.0% during Q3 2023.
  • Its 5-year average for Gross Margin is 186.79%, with a median of 81.35% in 2021.
  • As far as peak fluctuations go, TherapeuticsMD's Gross Margin surged by 20060400bps in 2022, and later crashed by -19824500bps in 2023.
  • Over the past 5 years, TherapeuticsMD's Gross Margin (Quarter) stood at 118.39% in 2019, then plummeted by -36bps to 75.28% in 2020, then fell by -1bps to 74.64% in 2021, then skyrocketed by 34bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Its Gross Margin stands at 100.0% for Q4 2023, versus 100.0% for Q3 2023 and 100.0% for Q2 2023.